Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health, diabetes care, gastrointestinal treatments and more.<\/p>\n\n\n\n
The company has a global footprint, with operations in over 50 countries and manufacturing facilities in India, the UK and the USA that are approved by major regulatory bodies like the US FDA, UK MHRA and Australian TGA. Its diverse product portfolio includes tablets, capsules, oral liquids, ointments and creams, supplied to supermarkets, pharmacy chains and wholesalers worldwide.<\/p>\n\n\n\n
Marksans is listed on the Bombay Stock Exchange (BSE: 524404) and the National Stock Exchange of India (NSE: MARKSANS), and emphasizes quality, regulatory compliance and R&D to drive growth in domestic and international markets.<\/p>\n\n\n\n
Operating revenue rose to \u20b9754.4 crore, registering a 10.6% year-on-year increase, driven by strong traction in the US and UK markets supported by new product launches and market share gains. Gross profit increased 14.3% YoY to \u20b9438.2 crore, with gross margin improving to 58.1%. EBITDA stood at \u20b9160.7 crore, with the EBITDA margin expanding by 217 basis points YoY to 21.3%. Earnings per share (EPS) for the quarter were \u20b92.5.<\/p>\n\n\n\n
For the nine-month period, operating revenue reached \u20b92,094.8 crore, up 9.4% YoY. Gross profit grew 10.3% YoY to \u20b91,208.2 crore, translating into a gross margin of 57.7%. EBITDA came in at \u20b9405.4 crore, with an EBITDA margin of 19.4%. EPS for 9M FY26 was \u20b96.0.<\/p>\n\n\n\n
The US and North America formulations business reported revenues of \u20b9412.4 crore in Q3 FY26, with performance in line with expectations and driven by volume growth supported by seasonal demand.<\/p>\n\n\n\n
Revenues from the UK and Europe formulations business stood at \u20b9258.2 crore in Q3 FY26, supported by new product launches and favorable currency movements.<\/p>\n\n\n\n
The Australia and New Zealand businesses recorded revenues of \u20b961.4 crore during Q3 FY26. The RoW business reported revenues of \u20b922.4 crore in Q3 FY26.<\/p>\n\n\n\n
Cash generated from operations amounted to \u20b9263.2 crore during 9M FY26, while capital expenditure of \u20b997.0 crore was incurred over the same period. The working capital cycle stood at approximately 151 days in Q3 FY26, and the company reported a cash balance of \u20b9824.2 crore as of 31 December 2025. Research and development spending was \u20b962.0 crore in 9M FY26, accounting for 3.0% of consolidated revenue.<\/p>\n","protected":false},"excerpt":{"rendered":"
About Marksans Pharma Limited Marksans Pharma Limited (NSE: MARKSANS) is an Indian pharmaceutical company headquartered in Mumbai, India, founded in 1992. It specializes in the research, development, manufacturing and marketing of pharmaceutical formulations, offering both over-the-counter (OTC) and prescription medicines across various therapeutic areas such as pain management, cardiovascular health, diabetes care, gastrointestinal treatments and […]<\/p>\n","protected":false},"author":2389,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941],"tags":[10162],"class_list":["post-179824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":153513,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-ltd-q1fy24-17-rise-in-profits\/","url_meta":{"origin":179824,"position":0},"title":"Marksans Pharma Ltd Q1FY24; 17% rise in Profits","author":"Karan_Singh","date":"August 14, 2023","format":false,"excerpt":"Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q1FY24 of \u20b9500.00 Crores up from \u20b9434.00 Crore year on year, a rise of 15.21%. Total Expenses for Q1FY24 of \u20b9414.00 Crores up from \u20b9374.00 Crores year on year, a\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-943.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162150,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-ltd-q4fy24-6-fall-in-profits\/","url_meta":{"origin":179824,"position":1},"title":"Marksans Pharma Ltd Q4FY24; 6% fall in Profits","author":"Chirag Gupta","date":"June 14, 2024","format":false,"excerpt":"Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q4FY24 of \u20b9560.00 Crores up from \u20b9486.00 Crore year on year, a rise of 15.23%. Total Expenses for Q4FY24 of \u20b9476.00 Crores up from \u20b9392.00 Crores year on year, a\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/06\/image-119.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":159132,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-ltd-q3fy24-34-rise-in-profits\/","url_meta":{"origin":179824,"position":2},"title":"Marksans Pharma Ltd Q3FY24; 34% rise in Profits","author":"Chirag Gupta","date":"February 23, 2024","format":false,"excerpt":"Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Financial Results: Marksans Pharma Ltd reported Revenues for Q3FY24 of \u20b9586.00 Crores up from \u20b9480.00 Crore year on year, a rise of 22.08%. Total Expenses for Q3FY24 of \u20b9478.00 Crores up from \u20b9418.00 Crores year on year, a\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-192.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170936,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":179824,"position":3},"title":"Marksans Pharma Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"September 4, 2025","format":false,"excerpt":"Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products. Presenting below are its Q1 FY26 earnings results. \u00a0 Q1 FY26 Earnings Results Revenue from Operations: \u20b9620 crores, up 5% YoY (Q1 FY25: \u20b9605.6 crores), and up 8.5% QoQ (Q4 FY25: \u20b9576.5 crores). Gross Profit:\u00a0\u20b9358.2 crores, up 8.9%\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Marksans Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/3-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":133596,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":179824,"position":4},"title":"Marksans Pharma Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 30, 2022","format":false,"excerpt":"https:\/\/youtu.be\/9PAJ7vTTG5E Key highlights from Marksans Pharma Limited (MARKSANS) Q1 FY23 Earnings Concall Management Update: MARKSANS said it aims to increase its R&D spend to 4-5% of sales over the coming years. The company also plans to expand its capacities over the next 12-18 months which would help expand margins in\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":138022,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":179824,"position":5},"title":"Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 25, 2022","format":false,"excerpt":"Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2389"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179824"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179824\/revisions"}],"predecessor-version":[{"id":179825,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179824\/revisions\/179825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}